Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.
Nadeem RiazEric ShermanIsaac X PeiHeiko SchöderMilan GrkovskiRamesh PaudyalNora KatabiPier SelenicaTakafumi N YamaguchiDaniel MaSimon K LeeRachna ShahRahul KumarFengshen KuoAbhirami RatnakumarNathan AleynickDavid BrownZhigang ZhangVaios HatzoglouLydia Y LiuAdriana SalcedoChiaojung J TsaiSean McBrideLuc G T MorrisJay BoyleBhuvanesh SinghDaniel S HigginsonRama R DamerlaArnaud da Cruz PaulaKatharine PriceEric J MooreJoaquin J GarciaRobert L FooteAlan HoRichard J WongTimothy A ChanSimon N PowellPaul C BoutrosJohn L HummAmita Shukla-DaveDavid PfisterJorge S Reis-FilhoNancy LeePublished in: Journal of the National Cancer Institute (2022)
Deescalation of radiotherapy to 30 Gy on the basis of intratreatment hypoxia imaging was feasible, safe, and associated with minimal toxicity. A DNA repair defect identified by WGS was predictive of response. Intratherapy personalization of chemoradiotherapy may facilitate marked deescalation of radiotherapy.